Current Therapy of Drugs in Amyotrophic Lateral Sclerosis

被引:38
作者
Lu, Haiyan [1 ]
Le, Wei Dong [2 ]
Xie, Ya-Ying [1 ]
Wang, Xiao-Ping [1 ]
机构
[1] Shanghai Jiao Tong Univ, Dept Neurol, Shanghai Peoples Hosp 1, Shanghai 200080, Peoples R China
[2] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA
基金
中国国家自然科学基金;
关键词
Amyotrophic lateral sclerosis; motor neuron disease; neurodegenerative disease; SOD1; mutations; riluzole; edaravone; pyrimethamine; TRANSGENIC MOUSE MODEL; DELAYS DISEASE ONSET; SUPEROXIDE-DISMUTASE; CEREBROSPINAL-FLUID; EXTENDS SURVIVAL; VALPROIC ACID; MUTANT SOD1; NEUROPROTECTIVE AGENTS; PROTEIN AGGREGATION; MOTOR-NEURONS;
D O I
10.2174/1570159X14666160120152423
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Amyotrophic lateral sclerosis (ALS), commonly termed as motor neuron disease (MND) in UK, is a chronically lethal disorder among the neurodegenerative diseases, meanwhile. ALS is basically irreversible and progressive deterioration of upper and lower motor neurons in the motor cortex, brain stem and medulla spinalis. Riluzole, used for the treatment of ALS, was demonstrated to slightly delay the initiation of respiratory dysfunction and extend the median survival of patients by a few months. In this study, the key biochemical defects were discussed, such as: mutant Cu/Zn superoxide dismutase, mitochondrial protectants, and anti-excitotoxic/ anti-oxidative / anti-inflammatory/ anti-apoptotic agents, so the related drug candidates that have been studied in ALS models would possibly be further used in ALS patients.
引用
收藏
页码:314 / 321
页数:8
相关论文
共 102 条
  • [1] Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
    Aggarwal, Swati P.
    Zinman, Lorne
    Simpson, Elizabeth
    McKinley, Jane
    Jackson, Katherine E.
    Pinto, Hanika
    Kaufman, Petra
    Conwit, Robin A.
    Schoenfeld, David
    Shefner, Jeremy
    Cudkowicz, Merit
    [J]. LANCET NEUROLOGY, 2010, 9 (05) : 481 - 488
  • [2] Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis
    Ahn, Suk-Won
    Jeon, Gye Sun
    Kim, Myung-Jin
    Shon, Jee-Heun
    Kim, Jee-Eun
    Shin, Je-Young
    Kim, Sung-Min
    Kim, Seung Hyun
    Ye, In-Hae
    Lee, Kwang-Woo
    Hong, Yoon-Ho
    Sung, Jung-Joon
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2014, 340 (1-2) : 112 - 116
  • [3] Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis
    Battaglia, Giuseppe
    Riozzi, Barbara
    Bucci, Domenico
    Di Menna, Luisa
    Molinaro, Gemma
    Pallottino, Simone
    Nicoletti, Ferdinando
    Bruno, Valeria
    [J]. NEUROBIOLOGY OF DISEASE, 2015, 74 : 126 - 136
  • [4] A CONTROLLED TRIAL OF RILUZOLE IN AMYOTROPHIC-LATERAL-SCLEROSIS
    BENSIMON, G
    LACOMBLEZ, L
    MEININGER, V
    BOUCHE, P
    DELWAIDE, C
    COURATIER, P
    BLIN, O
    VIADER, F
    PEYROSTPAUL, H
    DAVID, J
    MALOTEAUX, JM
    HUGON, J
    LATERRE, EC
    RASCOL, A
    CLANET, M
    VALLAT, JM
    DUMAS, A
    SERRATRICE, G
    LECHEVALLIER, B
    PEUCH, AJ
    NGUYEN, T
    SHU, C
    BASTIEN, P
    PAPILLON, C
    DURRLEMAN, S
    LOUVEL, E
    GUILLET, P
    LEDOUX, L
    ORVOENFRIJA, E
    DIB, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (09) : 585 - 591
  • [5] Onset and progression in inherited ALS determined by motor neurons and microglia
    Boillee, Severine
    Yamanaka, Koji
    Lobsiger, Christian S.
    Copeland, Neal G.
    Jenkins, Nancy A.
    Kassiotis, George
    Kollias, George
    Cleveland, Don W.
    [J]. SCIENCE, 2006, 312 (5778) : 1389 - 1392
  • [6] Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis
    Boll, Marie-Catherine
    Bayliss, Leo
    Vargas-Canas, Steven
    Burgos, Jorge
    Montes, Sergio
    Penaloza-Solano, Guillermo
    Rios, Camilo
    Alcaraz-Zubeldia, Mireya
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2014, 340 (1-2) : 103 - 108
  • [7] Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis
    Bordet, Thierry
    Buisson, Bruno
    Michaud, Magali
    Drouot, Cyrille
    Galea, Pascale
    Delaage, Pierre
    Akentieva, Natalia P.
    Evers, Alex S.
    Covey, Douglas F.
    Ostuni, Mariano A.
    Lacapere, Jean-Jacques
    Massaad, Charbel
    Schumacher, Michael
    Steidl, Esther-Marie
    Maux, Delphine
    Delaage, Michel
    Henderson, Christopher E.
    Pruss, Rebecca M.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 322 (02) : 709 - 720
  • [8] Riluzol as treatment of the amyotrophic lateral sclerosis
    Borrás-Blasco, J
    Plaza-Macías, I
    Navarro-Ruiz, A
    Perís-Martí, J
    Antón-Cano, A
    [J]. REVISTA DE NEUROLOGIA, 1998, 27 (160) : 1021 - 1027
  • [9] Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis
    Brettschneider, Johannes
    Widl, Karin
    Schattauer, Dagmar
    Ludolph, Albert C.
    Tumani, Hayrettin
    [J]. NEUROSCIENCE LETTERS, 2007, 416 (03) : 257 - 260
  • [10] Expression of a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis induces mitochondrial alteration and increase of cytosolic Ca2+ concentration in transfected neuroblastoma SH-SY5Y cells
    Carri, MT
    Ferri, A
    Battistoni, A
    Famhy, L
    Gabbianelli, R
    Poccia, F
    Rotilio, G
    [J]. FEBS LETTERS, 1997, 414 (02) : 365 - 368